Navigation Links
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Date:8/25/2008

The antibiotic surgical product may reduce incidence of surgical site

infections and reduce post-operative cost and complications

DEERFIELD, Ill. and ASHBURN, Va., Aug. 25 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced a licensing agreement with Innocoll Pharmaceuticals Ltd, a division of Innocoll, Inc., granting Baxter exclusive rights to market and distribute the company's gentamicin surgical implant in the United States. The gentamicin surgical implant will be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) therapy for prevention and treatment of surgical site infections (SSIs) in the United States. This agreement is expected to add to Baxter's biosurgical portfolio by giving surgeons an innovative option to help reduce risk of post-operative complications of SSIs during surgery.

The collagen-based implant is saturated with a high concentration of an antibiotic, gentamicin, designed to deliver the antibiotic directly to the target tissue while maintaining low levels of the drug in order to potentially reduce infection during and after surgery. The gentamicin surgical implant is fully biodegradable and can be left in the body after surgery. According to the Centers for Disease Control and Prevention, SSIs remain an ongoing problem for surgeons and are a burden on patients and the healthcare system, affecting more that 500,000 patients a year in the United States.

The product was developed using Innocoll's proprietary, collagen-based drug delivery technology, CollaRx, and is indicated outside of the United States as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of SSIs in both hard and soft tissues.

The implant is approved in 49 countries spanning Europe, Latin America, the Middle East, Africa and Asia. It is currently in two Phase III clinical trials in the United States to
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Baxter Declares Quarterly Dividend
2. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
3. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
4. Baxters Board of Directors Declares Quarterly Dividend
5. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
10. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
11. Baxter Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Oven Industries Inc. announces ... 5R6-900 temperature controller has many user-friendly benefits. Contained all ... the wall as a self-contained temperature control ... detail makes the device unique, as well as highly ... also be used universally, which allows the user to ...
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... 17, 2013  Yongye International, Inc. (NASDAQ: ... manufacturer, and distributor of crop nutrient products in ... announced that, on May 16, 2013, the special committee ... "Board of Directors") was provided a letter (the "Letter") ... ) Limited ("Abax") to Full Alliance International Limited ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The paradigm ... complex biological systems that can help predict the adverse ... Dr. Sergey Stepaniants, Head of Computational Biology at the ... biology tools to ensure high-quality genomics when used as ... be applied to complex data sets to identify key ...
Breaking Biology Technology:New Temperature Control Products Announced by Oven Industries Inc. 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... Alfacell Corporation (OTC Bulletin Board: ACEL) today reported ... U.S. Food and Drug Administration (FDA) to discuss the ... ONCONASE rolling New Drug Application (NDA) for the treatment ... pre-NDA meeting, the FDA provided guidance to the company ...
... PUBLISHED BY UNIVERSAL , NETTLETON, Miss., Jan. 27 ... that certain unauthorized inaccurate information is being published ... website, potentially other websites and publications, and an ... company has found errors in statements concerning the ...
... Scheduled for Tuesday, February 3, 2009 SAN DIEGO, Jan. ... ) announced today that the Company will report its ... Nasdaq market closes on Tuesday, February 3, 2009. Neurocrine ... to discuss its financial results and provide a Company ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results 2
(Date:5/17/2013)... a group of proteins in the brain responsible for ... target that could increase cell survival. , The discovery, ... and published in the EMBO journal with ... new therapies for stroke and other brain diseases. , ... which identified a protein, known as SUMO, responsible for ...
(Date:5/17/2013)... An international team of scientists ... and cell movement inside a living frog embryo in ... new method to advance biological research and the search ... University and the Karlsruher Institut fr Technologie in Germany, ... U.S. Department of Energy,s Argonne National Laboratory, released the ...
(Date:5/16/2013)... ancient shorelines to predict the stability of today,s largest ice ... from three million years ago, for example when Earth ... be evidence of a high sea level due to ice ... scientists to think that if the world,s largest ice sheets ... same in our modern, progressively warming world. , However, ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2New X-ray method shows how frog embryos could help thwart disease 2World's biggest ice sheets likely more stable than previously believed 2
... Technological University (NTU), and Israel,s number one university, ... new collaboration to jointly offer a Doctor of ... PhD degree programme is a university-wide agreement and ... Bioengineering. Significantly, the joint PhD degree will also ...
... the study and manipulation of human embryonic stem cells ... competition for a Hebrew University of Jerusalem researcher. ... Benvenisty of the Silberman Institute of Life Sciences was ... the Hebrew University of Jerusalem Board of Governors 73rd ...
... Guam,s territorial entomologist and Aubrey Moore, UOG extension entomologist, ... early June. Jackson was invited to assist in ... (Oryctes rhinoceros) population. This virus only infects rhino ... of the pest on other Pacific islands. The ...
Cached Biology News:NTU ramps up collaboration with Israel's top university 2NTU ramps up collaboration with Israel's top university 3Research on stem cells wins first prize for Hebrew University researcher 2Research on stem cells wins first prize for Hebrew University researcher 3Unusual rhino beetle behavior discovered 2